3 Year return
15.32%Investment Details
Calculate Returns
Based on past performance of this fund
Risk Involved
Your principal will be at
Very High Risk
Asset Under Management
₹7132.82 Cr.
Expense Ratio
0.92% (inclusive of GST)
Exit Load
1% if redeemed or switchd out on or efore completion of 1 Months from the date of allotment of units. NIl if redeemed or switched out after the completion of 1 Months from the date of allotment of units.
Tax Implications
Withdrawal within 1 year
Exit load + 15% tax on gains
Withdrawal after 1 year
10% tax on gains over ₹1 Lakh per financial year
Fund Holdings
Nippon India Mutual Fund Managers
SB
Sailesh Raj Bhan
Fund Manager since May 2018
Fund House Details
Nippon India Mutual Fund Asset management company
Peer Comparison
Comparison with other similar funds
Funds
|
3 Y Returns
|
ARQ Rating
|
---|---|---|
Invesco India PSU Equity Fund Direct Plan IDCW (Payout / Payout) |
42.14% |
0 |
Quant Infrastructure Fund IDCW Direct Plan Payout |
38.55% |
0 |
Invesco India Infrastructure Fund Direct Plan IDCW (Payout / Payout) |
37.43% |
0 |
Schemes by Nippon India Mutual Fund
List of mutual fund schemes by AMC
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan Monthly IDCW Payout
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan Monthly IDCW Reinvestment
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan IDCW Payout
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan IDCW Reinvestment
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan Growth
About Nippon India Pharma Fund Direct Plan IDCW Reinvestment
The Nippon India Pharma Fund Direct Plan IDCW Reinvestment is offered by Nippon Life India Asset Management Limited. The fund falls under the category of Sectoral/Thematic Funds. As a sectoral fund, it focuses on investing primarily in companies within the pharmaceutical sector. The reinvestment option allows the fund to reinvest the dividends earned to enhance the overall performance of the fund in the long run. This is an open-ended fund that allows investors to buy and sell units on any business day. The fund’s expense ratio is slightly higher than the category average.
Investment Objective of the Scheme
The main investment objective of the Nippon India Pharma Fund Direct Plan IDCW Reinvestment is to generate capital appreciation over the long term by predominantly investing in companies operating in the pharmaceutical sector. The fund aims to capitalise on growth opportunities within this specific sector.
Key Features of The Fund
5-year return | 25.54% |
Expense Ratio | 0.92% |
Fund Manager | Sailesh Raj Bhan |
Fund Size | ₹7132.82 Cr |
Risk Profile | Very High |
Is This Scheme Right for Me?
This fund might be suitable for investors who are bullish on the pharmaceutical sector and are looking for long-term capital growth. Since the fund predominantly invests in the pharma sector, investors should be prepared to take on higher risks. Before making an investment decision, interested investors should assess their own risk tolerance and returns expectation. Having a clear understanding of the pharma sector's dynamics is also essential.
AMC Contact Details
Name | Nippon India Mutual Fund |
Launch Date | June 1995 |
Addresss | Nippon Life India Asset Management Limited, 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai – 400 013 |
Contact | 1860 266 0111 |
customercare@nipponindiaim.in | |
Website | https://mf.nipponindiaim.com/ |
Disclaimer: Mutual funds are subject to market risk. Read all scheme-related documents carefully to make informed-decision.